Magdalena Czepnik

Magdalena Czepnik

Auto-generated profile, based on publicly available information

Magdalena Czepnik

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, OH 45267

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2017 in BMC Biology
Verified
Journal Article
Open access
PDF file
RWRyan G. Walker
Ryan G. Walker
MCMagdalena Czepnik
Magdalena Czepnik
EGErich J. Goebel
Erich J. Goebel
JMJason C. McCoy
Jason C. McCoy
Ana VujicAna Vujic
Ana Vujic
TTThomas B. Thompson
Thomas B. Thompson
Growth/differentiation factor 8 (GDF8) and GDF11 are two highly similar members of the transforming growth factor β (TGFβ) family. While GDF8 has been recognized as a negative regulator of muscle growth and differentiation, there are conflicting studies on the function of GDF11 and whether GDF11 has beneficial effects on age-related dysfunction. To address whether GDF8 and GDF11 are functionally identical, we compared their signaling and structural properties. Here we show that, despite their high similarity, GDF11 is a more potent activator of SMAD2/3 and signals more effectively through the type I activin-like receptor kinase receptors ALK4/5/7 than GDF8. Resolution of the GDF11:FS288 complex, apo-GDF8, and apo-GDF11 crystal structures reveals unique properties of both ligands, specifically in the type I receptor binding site. Lastly, substitution of GDF11 residues into GDF8 confers enhanced activity to GDF8. These studies identify distinctive structural features of GDF11 that enhance its potency, relative to GDF8; however, the biological consequences of these differences remain to be determined.

12 January 2018 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
TCThomas R Cotton
Thomas R Cotton
GFGerhard Fischer
Gerhard Fischer
XWXuelu Wang
Xuelu Wang
JMJason C McCoy
Jason C McCoy
MCMagdalena Czepnik
Magdalena Czepnik
MHMarko Hyvönen
Marko Hyvönen

17 July 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EGErich Goebel
Erich Goebel
RCRichard A. Corpina
Richard A. Corpina
CHCynthia S. Hinck
Cynthia S. Hinck
MCMagdalena Czepnik
Magdalena Czepnik
RCRoselyne Castonguay
Roselyne Castonguay
TTThomas B. Thompson
Thomas B. Thompson
TGFβ family ligands, which include the TGFβs, BMPs, and activins, signal by forming a ternary complex with type I and type II receptors. For TGFβs and BMPs, structures of ternary complexes have revealed differences in receptor assembly. However, structural information for how activins assemble a ternary receptor complex is lacking. We report the structure of an activin class member, GDF11, in complex with the type II receptor ActRIIB and the type I receptor Alk5. The structure reveals that receptor positioning is similar to the BMP class, with no interreceptor contacts; however, the type I receptor interactions are shifted toward the ligand fingertips and away from the dimer interface. Mutational analysis shows that ligand type I specificity is derived from differences in the fingertips of the ligands that interact with an extended loop specific to Alk4 and Alk5. The study also reveals differences for how TGFβ and GDF11 bind to the same type I receptor, Alk5. For GDF11, additional contacts at the fingertip region substitute for the interreceptor interactions that are seen for TGFβ, indicating that Alk5 binding to GDF11 is more dependent on direct contacts. In support, we show that a single residue of Alk5 (Phe 84 ), when mutated, abolishes GDF11 signaling, but has little impact on TGFβ signaling. The structure of GDF11/ActRIIB/Alk5 shows that, across the TGFβ family, different mechanisms regulate type I receptor binding and specificity, providing a molecular explanation for how the activin class accommodates low-affinity type I interactions without the requirement of cooperative receptor interactions.

18 January 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RWRyan G. Walker
Ryan G. Walker
JMJason C. McCoy
Jason C. McCoy
MCMagdalena Czepnik
Magdalena Czepnik
MMMelanie J. Mills
Melanie J. Mills
AHAdam Hagg
Adam Hagg
TTThomas B. Thompson
Thomas B. Thompson
Significance: GDF8 is a signaling protein that inhibits muscle mass. Inhibitors of GDF8 are highly sought as therapeutics for the treatment of muscle-wasting diseases. During synthesis, GDF8 is made as a precursor where the signaling segment is cleaved from the N-terminal prodomain, which remains associated and inhibits signaling. Activation involves an additional cleavage of the prodomain. We demonstrate GDF8 signaling could be gained through a conformational change where the prodomain remains associated with the signaling segment. Alteration of the prodomain can weaken the interactions causing GDF8 to signal, thus alleviating inhibition by the prodomain. This study illuminates how GDF8 transitions from an inhibited state to an active state—information that will help to understand the mechanism of GDF8 signaling.

1 July 2020 in Endocrinology
Verified
Journal Article
Open access
PDF file
KHKaitlin N Hart
Kaitlin N Hart
DPDavid Pépin
David Pépin
MCMagdalena Czepnik
Magdalena Czepnik
PDPatricia K Donahoe
Patricia K Donahoe
TTThomas B Thompson
Thomas B Thompson
Anti-Müllerian hormone (AMH) or Müllerian inhibiting substance is a unique member of the TGF-β family responsible for development and differentiation of the reproductive system. AMH signals through its own dedicated type II receptor, anti-Müllerian hormone receptor type II (AMHR2), providing an exclusive ligand-receptor pair within the broader TGF-β family. In this study, we used previous structural information to derive a model of AMH bound to AMHR2 to guide mutagenesis studies to identify receptor residues important for AMH signaling. Nonconserved mutations were introduced in AMHR2 and characterized in an AMH-responsive cell-based luciferase assay and native PAGE. Collectively, our results identified several residues important for AMH signaling within the putative ligand binding interface of AMHR2. Our results show that AMH engages AMHR2 at a similar interface to how activin and BMP class ligands bind the type II receptor, ACVR2B; however, there are significant molecular differences at the ligand interface of these 2 receptors, where ACVR2B is mostly hydrophobic and AMHR2 is predominately charged. Overall, this study shows that although the location of ligand binding on the receptor is similar to ACVR2A, ACVR2B, and BMPR2; AMHR2 uses unique ligand-receptor interactions to impart specificity for AMH.

27 September 2016 in Journal of Natural Products
Verified
Journal Article
Closed access
IAIngy I. Abdallah
Ingy I. Abdallah
MCMagdalena Czepnik
Magdalena Czepnik
RMRonald van Merkerk
Ronald van Merkerk
Wim QuaxWim Quax
Wim Quax